Therapeutic Exploratory (Phase II)

3,454 trials 1,368 recruiting

Filter these 3,454 trials by condition, country, sponsor and more.

Open in Search →

A study to evaluate the efficacy and safety of frexalimab, brivekimig or rilzabrutinib in participants aged 16 to 75 years with primary foca… Recruiting

2024-511775-15-00 Immune system diseases 2025-01-17
Phase II randomized study evaluating a Pragmatic approach to Adoptive Cell Therapy (ACT) using an IL2 analog (ANV419) vs High dose IL2 after… Recruiting

2023-506400-99-00 Advanced selected solid tumors: melanoma, non-small cel 2025-01-15
A Phase II trial of ginisortamab in participants with metastatic pancreatic ductal adenocarcinoma Recruiting

2024-514129-43-00 Metastatic pancreatic ductal adenocarcinoma 2025-01-15
Pembrolizumab in progressive multifocal leukoencephalopathy (PML) in immunocompromised patients without HIV infection (PENALTY) Recruiting

2023-503520-31-00 Immunocompromised patients with PML (with an underlying 2025-01-15
CASPER-ATG-IPC 2023-015 : Reinforced prophylaxis of GVH in elderly patients with haematological malignancies receiving haploidentical alloge… Recruiting

2023-506648-18-00 haematological malignancies 2025-01-14
Efficacy and safety of prednisone in the treatment of idiosyncratic hepatotoxicity Recruiting

2024-513004-33-00 Hepatotoxicity 2025-01-14
Neoadjuvant [177Lu]Lu-PSMAI&T radioligand therapy (PSMA-RLT) for patients with oligometastatic prostate cancer diagnosed using [68Ga]Ga-PSMA… Recruiting

2024-519377-18-00 Prostate Carcinoma 2025-01-14
A phase 2A pilot study to assess the safety and efficacy of eltanexor in relapsed/refractory NPM1-mutated acute myeloid leukemia Recruiting

2024-514724-16-01 Acute Myeloid Leukemia 2025-01-14
MESOTHERAPY IN LATERAL EPICONDYLITIS, A RANDOMIZED, DOUBLE- BLIND STUDY TO COMPARE THE EFFICACY OF MESOTHERAPY WITH PIROXICAM AND LIDOCAINE … Recruiting

2024-519158-34-00 lateral epicondylitis 2025-01-10
Early immunotherapy with intravenous immunoglobulin, cyclophosphamide and methylprednisolone in patients with anti-Hu-associated paraneoplas… Recruiting

2023-506942-22-01 paraneoplastic sensory neuropathy with anti-Hu antibodi 2025-01-10
EBUL0. A 20-Week Multicentre, Open Study Assessing the Efficacy and Safety of Apremilast in Patients > 6 years of age with Epidermolysis bul… Recruiting

2023-508794-83-00 Epidermolysis bullosa simplex 2025-01-10
177Lu-PSMA as a systemic adjuvant treatment in patients with high and very high risk prostate cancer after radical treatment with locoregion… Recruiting

2023-504912-13-00 Prostate Cancer 2025-01-09
Quantification tools for a novel tau PET marker in a rare neurological disease: 18F-PI-2620 in progressive supranuclear palsy Recruiting

2023-508718-40-00 Progressive supranuclear palsy 2025-01-09
MITO 31- A phase II trial of Olaparib in patients with recurrent ovarian cancer wild type for germline and somatic BRCA 1 and 2 genes: The M… Recruiting

2024-516841-38-00 recurrent ovarian cancer wild type for germline and som 2025-01-09
Chronic anticoagulation in end-stage renal disease patients: pharmacocinetics and pharmacodynamic of a reduced dose regimen of rivaroxaban (… Recruiting

2023-505733-28-00 Chronic hemodialysis 2025-01-08
Phase I/II randomized clinical trial of allogeneic adipose tissue-derived mesenchymal stromal cells systemic infusion in severe systemic scl… Recruiting

2023-505977-34-00 Systemic sclerosis 2025-01-08
“The BAPTIST study” Baricitinib in calcium pyrophosphAte dePosiTion dIseaSe Trial – a proof of concept phase II clinical trial . Recruiting

2024-511864-95-00 calcium pyrophosphate deposition disease 2025-01-08
A phase II randomized clinical study of the combination of avelumab plus cetuximab as rechallenge strategy in pre-treated RAS/BRAF wild type… Recruiting

2024-519481-44-00 colorectal metastatic cancer 2025-01-08
Decreasing treatment for metastatic HER2-Positive Breast Cancer with undetectable cancer levels in blood tests Recruiting

2023-509811-98-00 Patients with HER2-positive locally advanced inoperable 2025-01-07
Sequential immunochemotherapy treatment with Pembrolizumab plus Dendritic Cell (DC) Vaccine followed by Trifluridine/Tipiracil plus Bevacizu… Recruiting

2024-514053-30-00 Metastatic colorectal cancer 2025-01-07
A WORLD-WIDE CLINICAL STUDY TO FIND OUT IF INTRAVENOUS RECOMBINANT HUMAN PLASMA GELSOLIN IS SAFE AND IS BENEFICIAL FOR TREATING ACUTE RESPIR… Recruiting

2023-510109-16-00 Acute Respiratory Distress Syndrome (ARDS) Due to Pneum 2025-01-06
Interest of post-operative chemotherapy in patients with localized uterine leiomyosarcoma suspected to have a high-risk of relapse based on … Recruiting

2023-506350-21-00 Localized, resected, FIGO stage I (2018 classification) 2025-01-06
RIO Trial Recruiting

2024-514564-13-00 HIV 2025-01-02
VICTOR: Venetoclax or Intensive Chemotherapy for Treatment Of Favourable Risk Acute Myeloid Leukaemia: a molecularly guided phase 2 study Recruiting

2024-516116-19-00 Acute Myeloid Leukaemia 2025-01-01